US20060051413A1 - Method of enhancing absorptions of transmucosal administration formulations - Google Patents
Method of enhancing absorptions of transmucosal administration formulations Download PDFInfo
- Publication number
- US20060051413A1 US20060051413A1 US10/935,899 US93589904A US2006051413A1 US 20060051413 A1 US20060051413 A1 US 20060051413A1 US 93589904 A US93589904 A US 93589904A US 2006051413 A1 US2006051413 A1 US 2006051413A1
- Authority
- US
- United States
- Prior art keywords
- medicament
- administration
- environment
- propranolol
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention is directed to a method for enhancing absorption of a medicament that is suitable for transmucosal administration, particularly to a method for enhancing absorption of a medicament suitable for sublingual administration.
- Transmucosal drug delivery system has been studied for years because it can avoid the liver first-pass effect.
- the study on this field focuses on how to enhance absorption of the drug.
- General approaches reported to enhance absorption include the use of various permeation enhancers such as bile salts, surfactants, organic solvents, chelating agents as well as salicylate and Azone®.
- Factors affecting the permeation of a drug via oral mucosa include solubility of the drug, partition coefficient, degree of ionization of the drug, and molecular size and weight of the drug. For a given drug, the molecular size and weight are fixed and cannot be changed. Changes in solubility and degree of ionization will influence partition coefficient and permeability. Therefore, optimization of combined solubility and ionization are variable factors to achieving maximum rate and extent of absorption through oral mucosa such as sublingual mucosa.
- a first aspect of the preferred embodiments provides a method for enhancing absorption of a medicament that is suitable for administering transmucosally, such as sublingually in a subject.
- the medicament used in the preferred embodiments includes a therapeutically effective amount of an active compound or a pharmaceutically acceptable form thereof, or a combination thereof and a pharmaceutically acceptable carrier.
- the inventors have found that maximum flux of ionized and non-ionized forms of an active compound of a medicament across the mucosal membrane can be achieved with the attainment of a pH in a mucosal medium by involving certain amount of buffering agents with the medicament.
- a second aspect of the preferred embodiments is to provide a method for enhancing absorption of a medicament comprising propranolol or a pharmaceutically acceptable form thereof that is administered transmucosally to a subject, comprising providing an environment of the administration with a pH range of about 7.2 to about 7.8.
- a third aspect of the preferred embodiments is to provide a medicament suitable for a transmucosal administration to a subject, comprising an effective amount of propranolol or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier, in which the medicament provides an environment of the administration with a pH range of about 7.2 to about 7.8.
- a fourth aspect of the preferred embodiments is to provide a method for treating cardiovascular diseases of a subject comprising transmucosally administering a therapeutically effective amount of propranolol or a pharmaceutically acceptable form thereof to the subject in an environment with a pH range of about 7.2 to about 7.8.
- the formulation of the preferred embodiments can significantly decrease the heart rate in a subject in a very short time, and can be used to treat cardiovascular related diseases (urgent medical conditions) such as atrial fibrillation with rapid heart rate, panic attacks with rapid heart rate, acute hypertension, headache and angina.
- cardiovascular related diseases include atrial fibrillation with rapid heart rate, panic attacks with rapid heart rate, acute hypertension, headache and angina.
- FIG. 1 shows heart rates of two healthy subjects after sublingually administering propranolol powder in various pH values
- FIG. 2 shows a change of heart rate after administered with equivalent sublingual dose of a buffered propranolol tablet of the preferred embodiments versus a conventional Inderal tablet in 2 healthy subjects.
- the preferred embodiments provide a method for enhancing absorption of a medicament that is suitably administrated transmucosally.
- the medicament is administered sublingually by adjusting the pH of the environment of administration of the medicament.
- pH max - log ⁇ ( Ka ⁇ S i S u ) ( I ) in which K a is the ionization constant (dissociation constant) of the active compound of the medicament in water, S i is the solubility of the ionized form of the compound, and S u is the solubility of the non-ionized form of the compound.
- S i and S u can be easily obtained by measuring the drug solubility at two extreme pH levels where the ionized or non-ionized species are dominating.
- an ionizable medicament to transport across the mucosa includes both the ionized form and the non-ionized form of the medicament.
- the overall steady-state flux (J ss ) and the apparent permeability coefficient (P app ) of a medicament across the mucosa are the summations of the individual contribution from both the ionized and the non-ionized forms.
- J ss(u) and J ss(i) are the steady-state flux of the ionized form and the non-ionized form of the medicament, respectively;
- Q u and Q i are the accumulated amount of the ionized form and the non-ionized form of the medicament penetrated across the mucosa, respectively;
- A is the surface area of the mucosa;
- C 0 is the loading concentration of the medicament;
- P i and P u are the permeability coefficient of the ionized form and the non-ionized form, respectively;
- X i and X u are the fraction of the ionized form and the non-ionized form, respectively; and
- C i and C u are the concentration of the ionized and non-ionized forms, respectively.
- the term “absorption”, unless specified otherwise, means “penetration” of the active compound of the medicament through the mucosa.
- transmucosal means any route of the administration via the mucosal membrane. Examples include, but are not limited to, sublingual, nasal, vaginal and rectal. In the preferred embodiments, the administration is preferably performed sublingually.
- environment or “environment of an administration” means an environment where an active compound of a medicament is absorbed by permeation across the mucosa.
- the environment is saliva, which contains the drug and is “bathing” the sublingual mucosal membrane.
- subject means animals and human. Human is preferable in the preferred embodiments.
- the method of the preferred embodiments which provides an environment with a certain pH includes providing the environment with a preferable pH during the administration of the medicament, and making a suitable formulation of the medicament in such a way that the medicament itself can provide the environment with a desired pH.
- the latter is preferably.
- buffering agents are preferably involved in the formulation.
- Buffering agents that can be used in the preferred embodiments will be obvious for those skilled in the art. Please see “Handbooks Pharmaceutical Excipients (Second Edition), edited by Ainley Wade and Paul J W Weller, The Pharmaceutical Press London, 1994”, which is incorporated herein by reference.
- Exemplified buffering agents include, but are not limited to, phosphates, such as sodium phosphate; phosphates monobasic, such as sodium dihydrogen phosphate and potassium dihydrogen phosphate; phosphates dibasic, such as disodium hydrogen phosphate and dipotassium hydrogen phosphate; citrates, such as sodium citrate (anhydrous or dehydrate); bicarbonates, such as sodium bicarbonate and potassium bicarbonate.
- the amount of buffering agents used in the medicament is readily determined by those skilled in the art, which depend on preferable pH values.
- the medicaments of the preferred embodiments can include various formulations dependent on the dosage forms or formulations of administration.
- the medicament can be in the form of tablets, pills, pellets, powders or sprays.
- suitable formulations include, but are not limited to, ointments, capsules, solutions, syrups, drops, granules and suppositories.
- the medicament can include a therapeutically effective amount of an active compound or a pharmaceutically acceptable form thereof or either entity and a pharmaceutically acceptable carrier.
- the active compounds include, but are not limited to, propranolol, scopolamine, and estradiol. In the preferred embodiments, propranolol is preferable.
- the carrier suitably used in the preferred embodiments depends on the specific formulation of the medicament, which is known by those skilled in the art.
- the carriers include, without limitation, fillers, binders, lubricants, diluents, sweetening and flavoring agents, preservatives, disintegrators, grilling agents, permeation enhancers.
- the carriers include starch, gelatin, natural sugars, corn, natural and synthetic gums such as acacia, sodium alginate, methylcellulose, carboxymethylcellulose, polyethylene glycol, waxes, boric acid, sodium benzoate, sodium acetate, sodium chloride, agar, bentonite, agar gum, stearates such as sodium stearate, HPMC, and palmitic acid, dimethyl sulfoxide, N,N-dimethyl acetamide, N,N-dimethylformamide, 2-pyrrolidone, 1-methyl-2-pyrrolidone, 1,5-dimethyl-2-pyrrolidone, 1-ethyl-2-pyrrolidone, 2-pyrrolidone-5-carboxylic acid, N,N-dimethyl-m-toluamide, urea, ethyl acetate, 1-dodecylazacycloheptan-2-one (Azone®), oleic acid, ethylene vinylacetate copo
- Medicaments suitably used in the preferred embodiments are those suitably administered transmucosally which are well known by one skilled in the art.
- Propranolol 1-(isopropylamino)-3-(1-naphthyloxy)-2-propanol, a nonselective ⁇ 1 and ⁇ 2 -adrenergic antagonist, has been widely used in the treatment of various cardiovascular diseases such as essential arterial hypertension, ischemic heart disease and atrial fibrillation.
- cardiovascular diseases such as essential arterial hypertension, ischemic heart disease and atrial fibrillation.
- injection and oral tablet are the only two dosage forms marketed commercially.
- Intravenous or intramuscular administration of propranolol can achieve fast onset of action. However, they are inconvenient and not suitable for self-medication.
- the preferred embodiments provide a method for enhancing the absorption of a medicament comprising propranolol or a pharmaceutically acceptable form thereof that is administered transmucosally in a subject, comprising providing an environment for the administration with a pH range of about 7.2 to about 7.8; and a medicament of propranolol that is suitably administered sublingually to a subject.
- the medicament propranolol of the preferred embodiments comprises an effective amount of propranolol or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier, provided that the medicament provides an environment of the administration with a pH range of about 7.2 to about 7.8.
- the medicament contains an effective amount of propranolol or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier as described above, which can be formulated as a tablet, pill, pellet, spray, or powder, preferably as a tablet for sublingual administration.
- active compound propranolol can be used in the form of any pharmaceutically acceptable form such as free base, acidic salts, hydrates thereof, and acidic salts of the hydrates.
- the acidic salt form of propranolol is preferable because propranolol is a weak base.
- the acidic salts include, but are not limited to, a salt with inorganic acids such as hydrochloride, sulfate, and phosphate; and a salt with organic acids such as maleate, benzsulfonate acid, and citrate.
- buffering agents chosen include sodium bicarbonate, sodium phosphate, or a combination of borates and sodium hydroxide.
- buffering agents Na 2 HPO 4 , Na 2 HPO 4 —NaH 2 PO 4 , Na 2 HPO 4 -citric acid, and Tris-HCl Preferable examples include buffering agents Na 2 HPO 4 , Na 2 HPO 4 —NaH 2 PO 4 , Na 2 HPO 4 -citric acid, and Tris-HCl.
- disodium hydrogen phosphate by weight of about 10-25%, was found to effectively control the pH of saliva to be about 7.2 to about 7.8.
- the medicament of propranolol of the preferred embodiments comprises an effective amount of an active component, and a suitable carrier.
- effective amount means about 0.01 to about 99.99% in the formulation by weight.
- the active compound propranolol accounts for about 1-90% in the formulation by weight. More preferably, the active component accounts for about 2-50% in the formulation by weight, and most preferably, about 5-10% in the formulation by weight.
- the amount of the active component mentioned in the preferred embodiments means the amount of free compound of propranolol.
- the formulation of the preferred embodiments can be prepared to contain an amount of propranolol as those commercially available such as about 10 mg, 20 mg, 40 mg, or 80 mg in a tablet. It is also suitable that the formation may contain propranolol in an amount less than that commercially available, when it is used for urgent situations. Those skilled in the art will readily determine a suitable amount of propranolol in a specific formulation suitable for a given patient.
- Propranolol powder was mixed with magnesium stearate. To the resulting mixture was added other components, and then commingled in a V-blender for 15 minutes. The thoroughly blended composition was compressed into 1,000 plain tablets, each with 5 mm in diameter and 2-3 mm in thickness.
- a Dinamap BP monitor Wipro GE Co., USA was used to record systolic, diastolic, and mean blood pressure and heart rate every minute for 10 minutes before administration of sublingual propranolol. After sublingual administration, each subject was refrained from swallowing any propranolol or saliva until about 25 minutes, then the saliva was spit out and collected for pH measurement. Subsequently the mouth was rinsed 4 times with pure water. Pharmacodynamic parameters such as heart rate and blood pressure were measured. The heart rate change is shown in FIG. 1 and results reported as mean ⁇ SD. The blood pressure changes were variable and no significant hypotension occurred.
- the reduction of heart rate was highly dependent on the pH of saliva achieved from various buffering agents in the formulations ( FIG. 1 ).
- Subjects receiving formulation 3 showed a drop of more than 10% of heart rate following 10 minutes of administration of sublingual propranolol, which is much faster onset of action than other formulation with different saliva pH.
- Propranolol hydrochloride was ordered from Chang Zhou Guangming Biochemical Laboratories (BP 2000/USP24). Disodium hydrogen phosphate and HPMC (50 cps) were supplied by Sigma-Aldrich Co. (St. Louis, Mo., USA). Lactose monohydrate was supplied by Fisher Scientific UK Ltd. (Leicestershire, UK). Magnesium stearate was obtained form Wing Hing (Hong Kong).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed is a method for enhancing absorption of a medicament that is suitable for administering transmucosally to a subject by providing an environment of the administration with a suitable pH. A medicament of propranolol suitably administered sublingually is provided. The medicament of propranolol can be used for treating cardiovascular diseases.
Description
- 1. Field of the Invention
- The present invention is directed to a method for enhancing absorption of a medicament that is suitable for transmucosal administration, particularly to a method for enhancing absorption of a medicament suitable for sublingual administration.
- 2. Description of the Related Art
- Transmucosal drug delivery system has been studied for years because it can avoid the liver first-pass effect. The study on this field focuses on how to enhance absorption of the drug. General approaches reported to enhance absorption include the use of various permeation enhancers such as bile salts, surfactants, organic solvents, chelating agents as well as salicylate and Azone®.
- Factors affecting the permeation of a drug via oral mucosa, such as sublingual mucosa, include solubility of the drug, partition coefficient, degree of ionization of the drug, and molecular size and weight of the drug. For a given drug, the molecular size and weight are fixed and cannot be changed. Changes in solubility and degree of ionization will influence partition coefficient and permeability. Therefore, optimization of combined solubility and ionization are variable factors to achieving maximum rate and extent of absorption through oral mucosa such as sublingual mucosa.
- A first aspect of the preferred embodiments provides a method for enhancing absorption of a medicament that is suitable for administering transmucosally, such as sublingually in a subject. The medicament used in the preferred embodiments includes a therapeutically effective amount of an active compound or a pharmaceutically acceptable form thereof, or a combination thereof and a pharmaceutically acceptable carrier.
- The inventors have found that maximum flux of ionized and non-ionized forms of an active compound of a medicament across the mucosal membrane can be achieved with the attainment of a pH in a mucosal medium by involving certain amount of buffering agents with the medicament. The method of the preferred embodiments comprises providing an environment for the administration with a pH of about:
in which Ka is the ionization constant (dissociation constant) of the active compound in water, Si is the solubility of the ionized form of the compound, and Su is the solubility of the non-ionized form of the compound. - A second aspect of the preferred embodiments is to provide a method for enhancing absorption of a medicament comprising propranolol or a pharmaceutically acceptable form thereof that is administered transmucosally to a subject, comprising providing an environment of the administration with a pH range of about 7.2 to about 7.8.
- A third aspect of the preferred embodiments is to provide a medicament suitable for a transmucosal administration to a subject, comprising an effective amount of propranolol or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier, in which the medicament provides an environment of the administration with a pH range of about 7.2 to about 7.8.
- A fourth aspect of the preferred embodiments is to provide a method for treating cardiovascular diseases of a subject comprising transmucosally administering a therapeutically effective amount of propranolol or a pharmaceutically acceptable form thereof to the subject in an environment with a pH range of about 7.2 to about 7.8.
- Compared to a conventional formulation of propranolol, the formulation of the preferred embodiments can significantly decrease the heart rate in a subject in a very short time, and can be used to treat cardiovascular related diseases (urgent medical conditions) such as atrial fibrillation with rapid heart rate, panic attacks with rapid heart rate, acute hypertension, headache and angina.
-
FIG. 1 shows heart rates of two healthy subjects after sublingually administering propranolol powder in various pH values; and -
FIG. 2 shows a change of heart rate after administered with equivalent sublingual dose of a buffered propranolol tablet of the preferred embodiments versus a conventional Inderal tablet in 2 healthy subjects. - As stated above, the preferred embodiments provide a method for enhancing absorption of a medicament that is suitably administrated transmucosally. In one embodiment, the medicament is administered sublingually by adjusting the pH of the environment of administration of the medicament. We found that an active compound of a medicament can be significantly absorbed when an environment of the administration of the medicament is kept around:
in which Ka is the ionization constant (dissociation constant) of the active compound of the medicament in water, Si is the solubility of the ionized form of the compound, and Su is the solubility of the non-ionized form of the compound. Si and Su can be easily obtained by measuring the drug solubility at two extreme pH levels where the ionized or non-ionized species are dominating. - Theoretically, an ionizable medicament to transport across the mucosa includes both the ionized form and the non-ionized form of the medicament. The overall steady-state flux (Jss) and the apparent permeability coefficient (Papp) of a medicament across the mucosa are the summations of the individual contribution from both the ionized and the non-ionized forms. Therefore, the Jss and Papp of such a medicament permeate across the mucosa can be expressed by the following equations:
- In the above equations, Jss(u) and Jss(i) are the steady-state flux of the ionized form and the non-ionized form of the medicament, respectively; Qu and Qi are the accumulated amount of the ionized form and the non-ionized form of the medicament penetrated across the mucosa, respectively; A is the surface area of the mucosa; C0 is the loading concentration of the medicament; Pi and Pu are the permeability coefficient of the ionized form and the non-ionized form, respectively; Xi and Xu are the fraction of the ionized form and the non-ionized form, respectively; and Ci and Cu are the concentration of the ionized and non-ionized forms, respectively. Unlike Jss(u) and Jss(i), Pi and Pu are all independent of pH of the solution (environment). Therefore, we would expect that maximal Ci and Cu will be reached at an optimal pHmax, which will be the solubility of the ionized form (Si) and the non-ionized form (Su), respectively, and the maximal steady-state flux can be obtained accordingly.
- It is expected that the best flux of the medicament across the mucosa would be achieved if we could achieve the pHmax in the environment a certain amount of buffering agents in a specific formulation of the medicament.
- As used herein, the term “absorption”, unless specified otherwise, means “penetration” of the active compound of the medicament through the mucosa.
- The term “transmucosal”, unless specified otherwise, means any route of the administration via the mucosal membrane. Examples include, but are not limited to, sublingual, nasal, vaginal and rectal. In the preferred embodiments, the administration is preferably performed sublingually.
- The term “environment” or “environment of an administration” means an environment where an active compound of a medicament is absorbed by permeation across the mucosa. For example, when the administration is performed sublingually, the environment is saliva, which contains the drug and is “bathing” the sublingual mucosal membrane.
- The term “subject” means animals and human. Human is preferable in the preferred embodiments.
- The method of the preferred embodiments which provides an environment with a certain pH includes providing the environment with a preferable pH during the administration of the medicament, and making a suitable formulation of the medicament in such a way that the medicament itself can provide the environment with a desired pH. In the preferred embodiments, the latter is preferably. In this case, buffering agents are preferably involved in the formulation.
- Buffering agents that can be used in the preferred embodiments will be obvious for those skilled in the art. Please see “Handbooks Pharmaceutical Excipients (Second Edition), edited by Ainley Wade and Paul J W Weller, The Pharmaceutical Press London, 1994”, which is incorporated herein by reference. Exemplified buffering agents include, but are not limited to, phosphates, such as sodium phosphate; phosphates monobasic, such as sodium dihydrogen phosphate and potassium dihydrogen phosphate; phosphates dibasic, such as disodium hydrogen phosphate and dipotassium hydrogen phosphate; citrates, such as sodium citrate (anhydrous or dehydrate); bicarbonates, such as sodium bicarbonate and potassium bicarbonate. The amount of buffering agents used in the medicament is readily determined by those skilled in the art, which depend on preferable pH values.
- The medicaments of the preferred embodiments can include various formulations dependent on the dosage forms or formulations of administration. For example, if the medicament is administered sublingually, it can be in the form of tablets, pills, pellets, powders or sprays. Examples of other suitable formulations include, but are not limited to, ointments, capsules, solutions, syrups, drops, granules and suppositories. In any formulation, the medicament can include a therapeutically effective amount of an active compound or a pharmaceutically acceptable form thereof or either entity and a pharmaceutically acceptable carrier. Examples of the active compounds include, but are not limited to, propranolol, scopolamine, and estradiol. In the preferred embodiments, propranolol is preferable.
- The carrier suitably used in the preferred embodiments depends on the specific formulation of the medicament, which is known by those skilled in the art. The carriers include, without limitation, fillers, binders, lubricants, diluents, sweetening and flavoring agents, preservatives, disintegrators, grilling agents, permeation enhancers. Examples of the carriers include starch, gelatin, natural sugars, corn, natural and synthetic gums such as acacia, sodium alginate, methylcellulose, carboxymethylcellulose, polyethylene glycol, waxes, boric acid, sodium benzoate, sodium acetate, sodium chloride, agar, bentonite, agar gum, stearates such as sodium stearate, HPMC, and palmitic acid, dimethyl sulfoxide, N,N-dimethyl acetamide, N,N-dimethylformamide, 2-pyrrolidone, 1-methyl-2-pyrrolidone, 1,5-dimethyl-2-pyrrolidone, 1-ethyl-2-pyrrolidone, 2-pyrrolidone-5-carboxylic acid, N,N-dimethyl-m-toluamide, urea, ethyl acetate, 1-dodecylazacycloheptan-2-one (Azone®), oleic acid, ethylene vinylacetate copolymer, polyvincyl chloride, polyethylene, polydiethyl phthalate.
- Medicaments suitably used in the preferred embodiments are those suitably administered transmucosally which are well known by one skilled in the art.
- Propranolol, 1-(isopropylamino)-3-(1-naphthyloxy)-2-propanol, a nonselective β1 and β2-adrenergic antagonist, has been widely used in the treatment of various cardiovascular diseases such as essential arterial hypertension, ischemic heart disease and atrial fibrillation. At present, injection and oral tablet are the only two dosage forms marketed commercially. Intravenous or intramuscular administration of propranolol can achieve fast onset of action. However, they are inconvenient and not suitable for self-medication.
- Though oral administration of propranolol tablets has proven to be safe and effective in the treatment of atrial fibrillation, its onset of action is usually over 1 hr. Also, due to extensive hepatic first-pass effect, it has a short plasma half-life (2.8-4.4 hr), and a low bioavailability (10-30%).
- To overcome these drawbacks, the preferred embodiments provide a method for enhancing the absorption of a medicament comprising propranolol or a pharmaceutically acceptable form thereof that is administered transmucosally in a subject, comprising providing an environment for the administration with a pH range of about 7.2 to about 7.8; and a medicament of propranolol that is suitably administered sublingually to a subject. The medicament propranolol of the preferred embodiments comprises an effective amount of propranolol or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier, provided that the medicament provides an environment of the administration with a pH range of about 7.2 to about 7.8.
- In the preferred embodiments, the medicament contains an effective amount of propranolol or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier as described above, which can be formulated as a tablet, pill, pellet, spray, or powder, preferably as a tablet for sublingual administration. In the formulation, active compound propranolol can be used in the form of any pharmaceutically acceptable form such as free base, acidic salts, hydrates thereof, and acidic salts of the hydrates. In the preferred embodiments, the acidic salt form of propranolol is preferable because propranolol is a weak base. The acidic salts include, but are not limited to, a salt with inorganic acids such as hydrochloride, sulfate, and phosphate; and a salt with organic acids such as maleate, benzsulfonate acid, and citrate.
- It has been investigated that permeability across the sublingual mucosa is dependent on the concentration of non-ionized propranolol in the environment. When a formulation of propranolol provides saliva with pH of about 7.2 to about 7.8, propranolol should maintain relatively high solubility as well as high fraction of non-ionized form in the saliva of human oral cavity. Preferably, the formulation for sublingual delivery is at about pH 7.6. This can be confirmed by equation (I). For propranolol: Si is 22.118 (mg/ml), Su is 0.539 (mg/ml) and Ka is 10−9.23.
- To achieve this, buffering agents chosen include sodium bicarbonate, sodium phosphate, or a combination of borates and sodium hydroxide. Preferable examples include buffering agents Na2HPO4, Na2HPO4—NaH2PO4, Na2HPO4-citric acid, and Tris-HCl. Specifically, disodium hydrogen phosphate, by weight of about 10-25%, was found to effectively control the pH of saliva to be about 7.2 to about 7.8.
- The medicament of propranolol of the preferred embodiments comprises an effective amount of an active component, and a suitable carrier. The term of “effective amount” means about 0.01 to about 99.99% in the formulation by weight. Preferably, the active compound propranolol accounts for about 1-90% in the formulation by weight. More preferably, the active component accounts for about 2-50% in the formulation by weight, and most preferably, about 5-10% in the formulation by weight.
- The amount of the active component mentioned in the preferred embodiments, unless specified otherwise, means the amount of free compound of propranolol. The formulation of the preferred embodiments can be prepared to contain an amount of propranolol as those commercially available such as about 10 mg, 20 mg, 40 mg, or 80 mg in a tablet. It is also suitable that the formation may contain propranolol in an amount less than that commercially available, when it is used for urgent situations. Those skilled in the art will readily determine a suitable amount of propranolol in a specific formulation suitable for a given patient.
- Ingredients Weight (g)
Ingredients Weight (g) Propranolol hydrochloride 40 Disodium hydrogen phosphate 40 Lactose monohydrate 109 HPMC 20 Magnesium stearate 2 - Propranolol powder was mixed with magnesium stearate. To the resulting mixture was added other components, and then commingled in a V-blender for 15 minutes. The thoroughly blended composition was compressed into 1,000 plain tablets, each with 5 mm in diameter and 2-3 mm in thickness.
- Ingredients Weight (g)
Ingredients Weight (g) Propranolol 20 Sodium dihydrogen phosphate 40 Lactose 129 HPMC 20 Magnesium stearate 2 - All ingredients were formed as 1,000 tablets in the same way as in Example 1.
- Ingredients Weight (g)
Ingredients Weight (g) Propranolol 20 Sodium dihydrogen phosphate 1.5 Disodium hydrogen phosphate 38.5 Lactose monohydrate 109 HPMC 20 Magnesium stearate 2 - All ingredients were formed as 1,000 tablets in the same way as in Example 1.
- I. Methods and Materials
- Two healthy male subjects took part in the preliminary pharmacodynamic investigation of sublingual administration of buffered propranolol powder with 4 different buffering capacities as shown in Table 1.
TABLE 1 Dosage Propranolol Saliva pH Disappeared Formulations Forms (mg) Buffering Agent (Mean) (% Mean) 1 Powder 20 0 7.13 45.64 2 Powder 20 38.2 mg Na2HPO4 and 7.37 48.34 1.8 mg NaH2PO4 3 Powder 20 40 mg Na2HPO4 7.64 55.56 4 Powder 20 20 mg NaHCO3 7.88 44.35 - The subjects had not taken any sublingual medicine 2 weeks prior to and during the period of the study. Alcohol and smoking were not permitted for 24 hr prior to, and for the duration of the study. Caffeine-containing products were also not allowed from 8 hr prior to, and during, each study period.
- The subjects were placed in a seated position for about 30 min prior to baseline measurements being made. A Dinamap BP monitor (Wipro GE Co., USA) was used to record systolic, diastolic, and mean blood pressure and heart rate every minute for 10 minutes before administration of sublingual propranolol. After sublingual administration, each subject was refrained from swallowing any propranolol or saliva until about 25 minutes, then the saliva was spit out and collected for pH measurement. Subsequently the mouth was rinsed 4 times with pure water. Pharmacodynamic parameters such as heart rate and blood pressure were measured. The heart rate change is shown in
FIG. 1 and results reported as mean±SD. The blood pressure changes were variable and no significant hypotension occurred. - II. Results
- The reduction of heart rate was highly dependent on the pH of saliva achieved from various buffering agents in the formulations (
FIG. 1 ).Subjects receiving formulation 3 showed a drop of more than 10% of heart rate following 10 minutes of administration of sublingual propranolol, which is much faster onset of action than other formulation with different saliva pH. - Moreover, the maximal reduction of heart rate was 17% for
formulation 3, whereas only 5-10% maximal reductions were found for the other 3 formulations. These results indicated thatformulation 3 could effectively enhance the sublingual absorption of propranolol and rapidly reduce the heart rate in comparison to other 3 formulations. - I. Materials
- Propranolol hydrochloride was ordered from Chang Zhou Guangming Biochemical Laboratories (BP 2000/USP24). Disodium hydrogen phosphate and HPMC (50 cps) were supplied by Sigma-Aldrich Co. (St. Louis, Mo., USA). Lactose monohydrate was supplied by Fisher Scientific UK Ltd. (Leicestershire, UK). Magnesium stearate was obtained form Wing Hing (Hong Kong).
-
Inderal 40 mg propranolol tablets were purchased from AstraZeneca UK Ltd. (Macclesfield Cheshire, UK). - II. Methods
- Two healthy male subjects took part in the preliminary pharmacodynamic investigation once with buffered sublingual propranolol tablets as prepared in Example 1 and the Inderal tablet, respectively. The procedure of this study was similar to that described in
Experiment 1 except that following the tablet, and the saliva was spit out in 8 minutes. - III. Results
- The saliva pH of the Inderal tablet and that of the buffered tablet of the preferred embodiments were shown in Table 2. These results were shown in
FIG. 2 . The results showed that the buffered formulation quickly reduced 8% heart rate after 10 min of sublingual administration. However, the effect of the Inderal tablet was delayed to over 15 minutes and only a 6% reduction of heart rate. The heart rate continued to decrease with both the formulations, reaching a maximum effect around 20 minutes. The mean maximum effect of the buffered propranolol tablet was about 12% reduction whereas the Inderal tablet only about 7% reduction. The effect on the blood pressure was variable following both the formulations and no significant hypotension was observed.TABLE 2 Saliva pH Dosage forms (Mean ± SD) (n = 2) Inderal tablet 6.82 ± 0.10 Buffered tablet 7.52 ± 0.05 - Many modifications and variations of the embodiments described herein may be made without departing from the scope, as is apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only.
Claims (25)
1. A method for enhancing absorption of a medicament that is suitable for transmucosal administration to a subject, said method comprising providing an environment for the administration with a pH of about:
in which Ka is the ionization constant (dissociation constant) of the compound in water, Si is the solubility of the ionized form of the compound, and Su is the solubility of the non-ionized form of the compound.
2. The method of claim 1 , wherein the pH of the environment is provided by a buffering agent in the medicament.
3. The method of claim 2 , wherein the environment of administration is in the oral mucosa.
4. The method of claim 3 , wherein the environment of administration is a sublingual environment.
5. The method of claim 1 , wherein the medicament is propanolol.
6. The method of claim 1 , wherein the medicament is selected from the group consisting of scopolamine and estradiol.
7. A method for enhancing absorption of a medicament comprising propranolol or a pharmaceutically acceptable form thereof that is administered transmucosally to a subject, comprising providing an environment for the administration with a pH in the range from about 7.2 to about 7.8.
8. The method of claim 7 , wherein the medicament is administered sublingually.
9. The method of claim 8 , wherein the pH is about 7.6.
10. The method of claim 8 , wherein the pharmaceutically acceptable form is an acidic salt.
11. The method of claim 10 , wherein the salt is hydrochloride.
12. The method of claim 8 , wherein the medicament comprises a buffering agent.
13. The method of claim 12 , wherein the buffering agent is a phosphate buffer.
14. The method of claim 13 , wherein the buffering agent is disodium hydrogen phosphate, sodium dihydrogen phosphate or a combination thereof.
15. A medicament suitable for transmucosal administration to a subject, comprising an effective amount of propranolol or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier, wherein the medicament provides an environment of the administration with a pH of about 7.2 to about 7.8.
16. The medicament of claim 15 , wherein the pH is from about 7.6.
17. The medicament of claim 15 , wherein the pharmaceutically acceptable form is a salt.
18. The medicament of claim 17 , wherein the salt is hydrochloride.
19. The medicament of claim 15 , wherein the medicament comprises a buffering agent.
20. The medicament of claim 19 , wherein the buffering agent is a phosphate buffer.
21. The medicament of claim 20 , wherein the buffering agent is disodium hydrogen phosphate, sodium dihydrogen phosphate or a combination thereof.
22. The medicament of claim 15 , wherein the medicament is formulated as a tablet.
23. The medicament of claim 22 , wherein the tablet contains propranolol of from about 20 mg to about 80 mg.
24. A method for treating cardiovascular diseases of a subject comprising transmucosal administration of a therapeutically effective amount of propanolol to the subject in an environment with a pH range of about 7.2 to about 7.8.
25. The method of claim 24 , wherein the administration is performed sublingually, and the pH is about 7.6.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/935,899 US20060051413A1 (en) | 2004-09-08 | 2004-09-08 | Method of enhancing absorptions of transmucosal administration formulations |
US11/220,491 US7329416B2 (en) | 2004-09-08 | 2005-09-07 | Method of enhancing absorptions of transmucosal administration formulations |
EP05783988A EP1786467A4 (en) | 2004-09-08 | 2005-09-08 | Method of enhancing absorptions of transmucosal administration formulations |
JP2007529313A JP2008512363A (en) | 2004-09-08 | 2005-09-08 | Methods for enhancing absorption of transmucosal preparations |
PCT/CN2005/001425 WO2006026922A1 (en) | 2004-09-08 | 2005-09-08 | Method of enhancing absorptions of transmucosal administration formulations |
AU2005282135A AU2005282135B2 (en) | 2004-09-08 | 2005-09-08 | Method of enhancing absorptions of transmucosal administration formulations |
CN200580030149A CN100594936C (en) | 2004-09-08 | 2005-09-08 | Method of enhancing absorptions of transmucosal administration formulations |
CA2577740A CA2577740C (en) | 2004-09-08 | 2005-09-08 | Method of enhancing absorptions of transmucosal administration formulations |
US12/017,260 US8012503B2 (en) | 2004-09-08 | 2008-01-21 | Method of enhancing absorptions of transmucosal administration formulations |
HK08101014.2A HK1107271A1 (en) | 2004-09-08 | 2008-01-25 | Method of enhancing absorptions of transmucosal administration formulations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/935,899 US20060051413A1 (en) | 2004-09-08 | 2004-09-08 | Method of enhancing absorptions of transmucosal administration formulations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/220,491 Continuation-In-Part US7329416B2 (en) | 2004-09-08 | 2005-09-07 | Method of enhancing absorptions of transmucosal administration formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060051413A1 true US20060051413A1 (en) | 2006-03-09 |
Family
ID=35996531
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/935,899 Abandoned US20060051413A1 (en) | 2004-09-08 | 2004-09-08 | Method of enhancing absorptions of transmucosal administration formulations |
US11/220,491 Active US7329416B2 (en) | 2004-09-08 | 2005-09-07 | Method of enhancing absorptions of transmucosal administration formulations |
US12/017,260 Active US8012503B2 (en) | 2004-09-08 | 2008-01-21 | Method of enhancing absorptions of transmucosal administration formulations |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/220,491 Active US7329416B2 (en) | 2004-09-08 | 2005-09-07 | Method of enhancing absorptions of transmucosal administration formulations |
US12/017,260 Active US8012503B2 (en) | 2004-09-08 | 2008-01-21 | Method of enhancing absorptions of transmucosal administration formulations |
Country Status (8)
Country | Link |
---|---|
US (3) | US20060051413A1 (en) |
EP (1) | EP1786467A4 (en) |
JP (1) | JP2008512363A (en) |
CN (1) | CN100594936C (en) |
AU (1) | AU2005282135B2 (en) |
CA (1) | CA2577740C (en) |
HK (1) | HK1107271A1 (en) |
WO (1) | WO2006026922A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060193784A1 (en) * | 2005-02-25 | 2006-08-31 | Peter Crooks | Scopolamine sublingual spray for the treatment of motion sickness |
US20080226715A1 (en) * | 2007-03-16 | 2008-09-18 | Albert Cha | Therapeutic compositions and methods |
US20100015183A1 (en) * | 2006-07-21 | 2010-01-21 | Bio Delivery Sciences International ,Inc. | Transmucosal delivery devices with enhanced uptake |
US20100190835A1 (en) * | 2009-01-23 | 2010-07-29 | Alexander Glomme | Pharmaceutical composition comprising aleglitazar |
US8940330B2 (en) | 2011-09-19 | 2015-01-27 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
US10420720B2 (en) * | 2008-01-22 | 2019-09-24 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7804995B2 (en) | 2002-07-02 | 2010-09-28 | Reald Inc. | Stereoscopic format converter |
EP1715853A4 (en) * | 2004-02-17 | 2012-07-18 | Transcept Pharmaceuticals Inc | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
KR20130042041A (en) * | 2005-05-25 | 2013-04-25 | 트랜스셉트 파마슈티칼스, 인코포레이티드 | Solid compositions and methods for treating middle-of-the night insomnia |
US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
WO2008067549A2 (en) * | 2006-11-30 | 2008-06-05 | Transcept Pharmaceuticals, Inc. | Stabilized zolpidem pharmaceutical compositions |
WO2009146104A1 (en) * | 2008-04-02 | 2009-12-03 | Accentia Biopharmaceuticals, Inc. | Formulations, devices and methods for treating and preventing mucositis |
US9248597B2 (en) * | 2012-04-02 | 2016-02-02 | Progressive Components International Corporation | Bubbler base |
WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
EP4011370A1 (en) | 2014-07-22 | 2022-06-15 | Magnolia Cns, Llc | Pharmaceutical compositions and method for the treatment of symptoms of panic and anxiety using beta adrenergic receptor antagonist and muscarinic receptor antagonist combinations |
US9855227B2 (en) | 2015-12-18 | 2018-01-02 | The Procter & Gamble Company | Quick dissolving diphenhydramine oral dosage form |
EP4157449A4 (en) * | 2020-05-26 | 2024-05-29 | Strategic Drug Solutions Inc | Formulations and methods for treating erectile dysfunction |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5855908A (en) * | 1984-05-01 | 1999-01-05 | University Of Utah Research Foundation | Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient |
US6255502B1 (en) * | 1996-07-11 | 2001-07-03 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522804A (en) * | 1983-01-03 | 1985-06-11 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulations of propranolol |
US5288498A (en) * | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
JP2801050B2 (en) * | 1985-05-01 | 1998-09-21 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | Compressed powder drug |
US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
US5132114A (en) * | 1985-05-01 | 1992-07-21 | University Of Utah Research Foundation | Compositions and methods of manufacture of compressed powder medicaments |
GB8522453D0 (en) * | 1985-09-11 | 1985-10-16 | Lilly Industries Ltd | Chewable capsules |
DE68928415T2 (en) * | 1989-09-05 | 1998-02-26 | Univ Utah Research Inst | METHOD AND COMPOSITIONS FOR ADMINISTRATING LIPOPHILE MEDICINES IN A DOSAGE AFTER THE DESIRED EFFECT |
US6197334B1 (en) * | 1998-04-13 | 2001-03-06 | Donald V. Renda | Lozenge and method of making |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
CN1163263C (en) * | 2000-01-07 | 2004-08-25 | 华中理工大学 | Polypeptide medicine as oral spray |
AU2001261744A1 (en) * | 2000-05-19 | 2001-12-03 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
CN1335182A (en) * | 2001-08-08 | 2002-02-13 | 华中科技大学 | Insulin spray for oral cavity and its prepn process |
US20050065175A1 (en) * | 2003-09-24 | 2005-03-24 | Xanodyne Pharmacal, Inc. | Oral transmucosal methadone |
US20090263476A1 (en) * | 2008-04-16 | 2009-10-22 | Jobdevairakkam Christopher N | Composition of Rapid Disintegrating Direct Compression Buccal Tablet |
-
2004
- 2004-09-08 US US10/935,899 patent/US20060051413A1/en not_active Abandoned
-
2005
- 2005-09-07 US US11/220,491 patent/US7329416B2/en active Active
- 2005-09-08 EP EP05783988A patent/EP1786467A4/en not_active Withdrawn
- 2005-09-08 AU AU2005282135A patent/AU2005282135B2/en not_active Ceased
- 2005-09-08 CA CA2577740A patent/CA2577740C/en not_active Expired - Fee Related
- 2005-09-08 CN CN200580030149A patent/CN100594936C/en not_active Expired - Fee Related
- 2005-09-08 WO PCT/CN2005/001425 patent/WO2006026922A1/en active Application Filing
- 2005-09-08 JP JP2007529313A patent/JP2008512363A/en active Pending
-
2008
- 2008-01-21 US US12/017,260 patent/US8012503B2/en active Active
- 2008-01-25 HK HK08101014.2A patent/HK1107271A1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5855908A (en) * | 1984-05-01 | 1999-01-05 | University Of Utah Research Foundation | Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient |
US6255502B1 (en) * | 1996-07-11 | 2001-07-03 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006093786A2 (en) * | 2005-02-25 | 2006-09-08 | University Of Kentucky Research Foundation | Scopolamine sublingual spray |
WO2006093786A3 (en) * | 2005-02-25 | 2006-12-07 | Univ Kentucky Res Found | Scopolamine sublingual spray |
US20060193784A1 (en) * | 2005-02-25 | 2006-08-31 | Peter Crooks | Scopolamine sublingual spray for the treatment of motion sickness |
US9597288B2 (en) | 2006-07-21 | 2017-03-21 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
US20100015183A1 (en) * | 2006-07-21 | 2010-01-21 | Bio Delivery Sciences International ,Inc. | Transmucosal delivery devices with enhanced uptake |
US9655843B2 (en) | 2006-07-21 | 2017-05-23 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
US20080226715A1 (en) * | 2007-03-16 | 2008-09-18 | Albert Cha | Therapeutic compositions and methods |
US10420720B2 (en) * | 2008-01-22 | 2019-09-24 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
US20100190835A1 (en) * | 2009-01-23 | 2010-07-29 | Alexander Glomme | Pharmaceutical composition comprising aleglitazar |
US20130072529A1 (en) * | 2009-01-23 | 2013-03-21 | Hoffmann-La Roche Inc. | Pharmaceutical composition comprising aleglitazar |
US9259421B2 (en) | 2011-09-19 | 2016-02-16 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US9439900B2 (en) | 2011-09-19 | 2016-09-13 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US8940330B2 (en) | 2011-09-19 | 2015-01-27 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US10874661B2 (en) | 2011-09-19 | 2020-12-29 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US10946010B2 (en) | 2011-09-19 | 2021-03-16 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US11020388B2 (en) | 2011-09-19 | 2021-06-01 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US11020387B2 (en) | 2011-09-19 | 2021-06-01 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US11433066B2 (en) | 2011-09-19 | 2022-09-06 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
Also Published As
Publication number | Publication date |
---|---|
US20060051415A1 (en) | 2006-03-09 |
EP1786467A1 (en) | 2007-05-23 |
CA2577740A1 (en) | 2006-03-16 |
JP2008512363A (en) | 2008-04-24 |
CN100594936C (en) | 2010-03-24 |
WO2006026922A1 (en) | 2006-03-16 |
AU2005282135A1 (en) | 2006-03-16 |
CN101068571A (en) | 2007-11-07 |
US7329416B2 (en) | 2008-02-12 |
HK1107271A1 (en) | 2008-04-03 |
AU2005282135B2 (en) | 2009-01-22 |
EP1786467A4 (en) | 2010-09-01 |
CA2577740C (en) | 2011-03-15 |
US8012503B2 (en) | 2011-09-06 |
US20080132517A1 (en) | 2008-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7329416B2 (en) | Method of enhancing absorptions of transmucosal administration formulations | |
RU2436565C2 (en) | Disintegrating oral films | |
US20080131508A1 (en) | Oral transmucosal nicotine dosage form | |
ES2538460T3 (en) | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence | |
US20090263476A1 (en) | Composition of Rapid Disintegrating Direct Compression Buccal Tablet | |
RU2010123027A (en) | PHARMACEUTICAL COMPOSITIONS OF DUAL ACTION ON THE BASIS OF NADMOLECULAR STRUCTURES OF ANTAGONISTS / ANGIOTENZINE (ARB) RECEPTOR BLOCK AND NEUTRAL ENDEPEPTIDASE (NEP) INHIBITOR (NEP) | |
PT1998762E (en) | Solid dosage form containing a taste masked active agent | |
CA3097053C (en) | Edaravone pharmaceutical composition | |
US20090214442A1 (en) | Oral Transmucosal Nicotine Dosage Form | |
JP4090997B2 (en) | Perindopril oral dispersible pharmaceutical composition | |
KR20150002453A (en) | Chewable tablet formulation comprising tadalafil or a pharmaceutically acceptable salt thereof | |
JP2023506537A (en) | Transmucosal therapeutic system containing agomelatine | |
US9675551B2 (en) | Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof | |
JP2016527262A (en) | Oral film dosage form that is immediately wettable without surfactants and polyhydric alcohols | |
JP2002539165A (en) | Controlled release of sildenafil delivered by sublingual or buccal administration | |
JP2003520252A (en) | Terbinafine-containing pharmaceutical composition | |
WO2003075919A1 (en) | Tablet containing pilsicainide hydrochloride (dry) | |
AU2017317523B2 (en) | Pharmaceutical solution of Asenapine for sublingual or buccal use | |
JP2006528160A (en) | Oral dispersible pharmaceutical composition of antithrombotic compound | |
WO2014191414A1 (en) | Syrup formulation of salbutamol | |
RU2276982C2 (en) | Agent possessing with anti-inflammatory, analgesic and antipyretic effect as tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CHINESE UNIVERSITY OF HONG KONG, THE, CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHOW, SING SUM MOSES;WANG, YAN-FENG;ZUO, ZHONG JOAN;REEL/FRAME:016149/0592 Effective date: 20041217 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |